Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

Stopped early · Phase 2

Conditions studied: Heparin-Induced Thrombocytopenia

In brief

The purpose of this study is to determine how safe and effective fondaparinux is in treating patients with suspected or confirmed heparin-induced thrombocytopenia (HIT).

Key facts

Study ID

NCT00673439

Run by

University of Louisville

People needed

3

Starts

2007-11-01

Expected to finish

2011-09-01

Last updated by the study team

2019-11-08

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• high risk for HIT based on "Four Ts score" of 6 or more

You may not qualify if…

• pulmonary emboli at the time of enrollment
• arterial thrombosis at the time of enrollment
• limb threatening phlegmasia cerulea dolens at the time of enrollment
• Calculated Creatinin Clearance less than 50 ml/hr
• platelet count less than 50
• Weight less than 50 kg
• pregnancy
• allergy to fondaparinux
• bacterial endocarditis
• history of neuraxial anesthesia and post-operative indwelling epidural catheter
• active major bleeding (hemodynamically significant or requiring transfusions)
• inability to give informed consent

Where it is running

• University of Louisville Hospital — Louisville, Kentucky, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.